JP2018508593A - がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ - Google Patents

がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ Download PDF

Info

Publication number
JP2018508593A
JP2018508593A JP2018500281A JP2018500281A JP2018508593A JP 2018508593 A JP2018508593 A JP 2018508593A JP 2018500281 A JP2018500281 A JP 2018500281A JP 2018500281 A JP2018500281 A JP 2018500281A JP 2018508593 A JP2018508593 A JP 2018508593A
Authority
JP
Japan
Prior art keywords
antibody
entinostat
administered
cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018500281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508593A5 (enExample
Inventor
グッドナウ ロバート
グッドナウ ロバート
オルデントリッヒ ピーター
オルデントリッヒ ピーター
Original Assignee
シンダックス ファーマシューティカルズ，インコーポレイティド
シンダックス ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56977796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018508593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シンダックス ファーマシューティカルズ，インコーポレイティド, シンダックス ファーマシューティカルズ，インコーポレイティド filed Critical シンダックス ファーマシューティカルズ，インコーポレイティド
Publication of JP2018508593A publication Critical patent/JP2018508593A/ja
Publication of JP2018508593A5 publication Critical patent/JP2018508593A5/ja
Priority to JP2021130582A priority Critical patent/JP7540980B2/ja
Priority to JP2024072421A priority patent/JP2024091945A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2018500281A 2015-03-20 2016-03-18 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ Pending JP2018508593A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021130582A JP7540980B2 (ja) 2015-03-20 2021-08-10 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
JP2024072421A JP2024091945A (ja) 2015-03-20 2024-04-26 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562136303P 2015-03-20 2015-03-20
US62/136,303 2015-03-20
US201562137601P 2015-03-24 2015-03-24
US62/137,601 2015-03-24
PCT/US2016/023298 WO2016154068A1 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130582A Division JP7540980B2 (ja) 2015-03-20 2021-08-10 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ

Publications (2)

Publication Number Publication Date
JP2018508593A true JP2018508593A (ja) 2018-03-29
JP2018508593A5 JP2018508593A5 (enExample) 2019-03-07

Family

ID=56977796

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018500281A Pending JP2018508593A (ja) 2015-03-20 2016-03-18 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
JP2021130582A Active JP7540980B2 (ja) 2015-03-20 2021-08-10 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
JP2024072421A Pending JP2024091945A (ja) 2015-03-20 2024-04-26 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021130582A Active JP7540980B2 (ja) 2015-03-20 2021-08-10 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
JP2024072421A Pending JP2024091945A (ja) 2015-03-20 2024-04-26 がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ

Country Status (12)

Country Link
US (3) US11324822B2 (enExample)
EP (1) EP3270966B1 (enExample)
JP (3) JP2018508593A (enExample)
KR (1) KR20170124604A (enExample)
CN (1) CN107614011A (enExample)
AU (2) AU2016235434B2 (enExample)
BR (1) BR112017020002A2 (enExample)
CA (1) CA2980297A1 (enExample)
ES (1) ES2986548T3 (enExample)
IL (3) IL307850A (enExample)
MX (1) MX2017012113A (enExample)
WO (1) WO2016154068A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021535187A (ja) * 2018-06-15 2021-12-16 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｓ−エクオールを用いた黒色腫の処置及び予防方法
JP2022548507A (ja) * 2019-09-04 2022-11-21 クリスタルジェノミクス・インコーポレイテッド Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物
US12070443B2 (en) 2018-06-15 2024-08-27 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR102631377B1 (ko) 2015-09-02 2024-01-29 신닥스 파마슈티컬스, 인크. 조합 요법을 위한 환자의 선별
US20190183870A1 (en) * 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
JP2019503386A (ja) 2016-01-28 2019-02-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP7090611B2 (ja) * 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
KR102651568B1 (ko) 2017-05-19 2024-03-25 신닥스 파마슈티컬스, 인크. 조합 요법
SG11202001760VA (en) * 2017-09-08 2020-03-30 4Sc Ag Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy
WO2019191764A1 (en) 2018-03-28 2019-10-03 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
KR20250115460A (ko) 2018-05-07 2025-07-30 신닥스 파마슈티컬스, 인크. 병용 요법을 위한 환자의 선정
TW202128224A (zh) * 2019-12-23 2021-08-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法
WO2024222705A1 (zh) * 2023-04-25 2024-10-31 深圳微芯生物科技股份有限公司 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
WO2015016718A1 (en) * 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US8987067B2 (en) * 2013-03-01 2015-03-24 International Business Machines Corporation Segmented guard ring structures with electrically insulated gap structures and design structures thereof
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
US10869926B2 (en) * 2014-07-15 2020-12-22 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
KR102513870B1 (ko) * 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
CA2990687A1 (en) * 2015-06-29 2017-01-05 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
KR102631377B1 (ko) * 2015-09-02 2024-01-29 신닥스 파마슈티컬스, 인크. 조합 요법을 위한 환자의 선별

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
WO2015016718A1 (en) * 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, vol. Vol. 26, Issue suppl. 9, JPN6019045375, December 2015 (2015-12-01), pages 461, ISSN: 0004321515 *
CANCER RESEARCH, vol. Vol. 74, No. 19, Supplement, JPN6020028936, 2014, pages 4090, ISSN: 0004483121 *
CLINICAL CANCER RESEARCH, vol. 20, no. 9, JPN6019045373, 2014, pages 2242 - 2248, ISSN: 0004321514 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021535187A (ja) * 2018-06-15 2021-12-16 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｓ−エクオールを用いた黒色腫の処置及び予防方法
US12064413B2 (en) 2018-06-15 2024-08-20 The Board Of Regents Of The University Of Texas System Methods of treating melanoma with S-equol
US12070443B2 (en) 2018-06-15 2024-08-27 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
JP2022548507A (ja) * 2019-09-04 2022-11-21 クリスタルジェノミクス・インコーポレイテッド Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物
JP7644988B2 (ja) 2019-09-04 2025-03-13 クリスタルジェノミクス・インコーポレイテッド Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物

Also Published As

Publication number Publication date
IL254529B2 (en) 2024-05-01
AU2016235434A1 (en) 2017-10-12
IL254529B1 (en) 2024-01-01
ES2986548T3 (es) 2024-11-11
NZ735686A (en) 2024-07-26
RU2017134315A3 (enExample) 2019-09-12
EP3270966A1 (en) 2018-01-24
US11324822B2 (en) 2022-05-10
US20240398944A1 (en) 2024-12-05
AU2022202954A1 (en) 2022-05-26
EP3270966A4 (en) 2018-10-17
BR112017020002A2 (en) 2018-06-19
IL307850A (en) 2023-12-01
HK1250142A1 (en) 2018-11-30
IL254529A0 (en) 2017-11-30
AU2016235434B2 (en) 2022-02-03
EP3270966B1 (en) 2024-05-01
CA2980297A1 (en) 2016-09-29
JP7540980B2 (ja) 2024-08-27
IL323063A (en) 2025-10-01
JP2021175754A (ja) 2021-11-04
JP2024091945A (ja) 2024-07-05
CN107614011A (zh) 2018-01-19
RU2017134315A (ru) 2019-04-03
KR20170124604A (ko) 2017-11-10
WO2016154068A1 (en) 2016-09-29
US20180078639A1 (en) 2018-03-22
MX2017012113A (es) 2018-07-06
US20230022573A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7540980B2 (ja) がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
JP2018519335A (ja) がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
KR102631377B1 (ko) 조합 요법을 위한 환자의 선별
JP2018538321A (ja) 卵巣がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
JP2024008964A (ja) 併用療法のための患者の選択
RU2796903C2 (ru) Комбинация ингибитора hdac и анти-pd-1 антитела для лечения рака
HK1250142B (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine
JP2025179057A (ja) 併用療法のための患者の選択

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20171109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20171109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210408